Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Epigenetic markers associated with metformin response and intolerance in drug-naive patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Distinct immune phenotypes in infants developing asthma during childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A dual-action peptide-containing hydrogel targets wound infection and inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sonia García-Calzón
  • Alexander Perfilyev
  • Mats Martinell
  • Monta Ustinova
  • Sebastian Kalamajski
  • Paul W Franks
  • Karl Bacos
  • Ilze Elbere
  • Jussi Pihlajamäki
  • Petr Volkov
  • Allan Vaag
  • Leif Groop
  • Marlena Maziarz
  • Janis Klovins
  • Emma Ahlqvist
  • Charlotte Ling
View graph of relations

Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However, many patients with T2D do not respond to or tolerate metformin well. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin. We explored whether blood-based epigenetic markers could discriminate metformin response and tolerance by analyzing genome-wide DNA methylation in drug-naïve patients with T2D at the time of their diagnosis. DNA methylation of 11 and 4 sites differed between glycemic responders/nonresponders and metformin-tolerant/intolerant patients, respectively, in discovery and replication cohorts. Greater methylation at these sites associated with a higher risk of not responding to or not tolerating metformin with odds ratios between 1.43 and 3.09 per 1-SD methylation increase. Methylation risk scores (MRSs) of the 11 identified sites differed between glycemic responders and nonresponders with areas under the curve (AUCs) of 0.80 to 0.98. MRSs of the 4 sites associated with future metformin intolerance generated AUCs of 0.85 to 0.93. Some of these blood-based methylation markers mirrored the epigenetic pattern in adipose tissue, a key tissue in diabetes pathogenesis, and genes to which these markers were annotated to had biological functions in hepatocytes that altered metformin-related phenotypes. Overall, we could discriminate between glycemic responders/nonresponders and participants tolerant/intolerant to metformin at diagnosis by measuring blood-based epigenetic markers in drug-naïve patients with T2D. This epigenetics-based tool may be further developed to help patients with T2D receive optimal therapy.

Original languageEnglish
Article numbereaaz1803
JournalScience translational medicine
Volume12
Issue number561
ISSN1946-6234
DOIs
Publication statusPublished - 16 Sep 2020

ID: 61552859